IL139172A0 - N- (3-ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4- quinazolinamine mesylate anhydrate and monohydrate - Google Patents

N- (3-ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4- quinazolinamine mesylate anhydrate and monohydrate

Info

Publication number
IL139172A0
IL139172A0 IL13917299A IL13917299A IL139172A0 IL 139172 A0 IL139172 A0 IL 139172A0 IL 13917299 A IL13917299 A IL 13917299A IL 13917299 A IL13917299 A IL 13917299A IL 139172 A0 IL139172 A0 IL 139172A0
Authority
IL
Israel
Prior art keywords
ethynylphenylamino
methoxyethoxy
monohydrate
bis
quinazolinamine mesylate
Prior art date
Application number
IL13917299A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of IL139172A0 publication Critical patent/IL139172A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13917299A 1998-04-29 1999-04-08 N- (3-ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4- quinazolinamine mesylate anhydrate and monohydrate IL139172A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29
PCT/IB1999/000612 WO1999055683A1 (en) 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Publications (1)

Publication Number Publication Date
IL139172A0 true IL139172A0 (en) 2001-11-25

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13917299A IL139172A0 (en) 1998-04-29 1999-04-08 N- (3-ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4- quinazolinamine mesylate anhydrate and monohydrate

Country Status (41)

Country Link
EP (1) EP1076652B1 (cs)
JP (1) JP4652569B2 (cs)
KR (1) KR100668412B1 (cs)
CN (2) CN101219999A (cs)
AP (1) AP1252A (cs)
AR (1) AR018201A1 (cs)
AT (1) ATE295839T1 (cs)
AU (1) AU759691C (cs)
BR (1) BR9910025A (cs)
CA (1) CA2330447C (cs)
CO (1) CO5060467A1 (cs)
CZ (1) CZ298230B6 (cs)
DE (1) DE69925366T2 (cs)
DZ (1) DZ2777A1 (cs)
EA (1) EA002836B1 (cs)
EG (1) EG24000A (cs)
ES (1) ES2238825T3 (cs)
GT (1) GT199900063A (cs)
HN (1) HN1999000057A (cs)
HU (1) HU227569B1 (cs)
ID (1) ID27198A (cs)
IL (1) IL139172A0 (cs)
MA (1) MA26624A1 (cs)
ME (1) MEP42008A (cs)
MX (1) MXPA00010610A (cs)
MY (1) MY136033A (cs)
NO (1) NO317301B1 (cs)
NZ (1) NZ508154A (cs)
OA (1) OA11769A (cs)
PA (1) PA8471001A1 (cs)
PE (1) PE20000441A1 (cs)
PL (1) PL196940B1 (cs)
RS (1) RS50081B (cs)
SA (1) SA99200216B1 (cs)
TN (1) TNSN99079A1 (cs)
TR (1) TR200003166T2 (cs)
TW (1) TWI248437B (cs)
UA (1) UA60363C2 (cs)
UY (1) UY26099A1 (cs)
WO (1) WO1999055683A1 (cs)
ZA (1) ZA992972B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1633870B1 (en) 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
AU2004247418B2 (en) 2003-06-10 2009-11-05 F. Hoffmann-La Roche Ag 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005107747A2 (en) 2004-05-06 2005-11-17 Bioresponse, Llc Diindolymethane formulations for the treatment of leiomyomas
CA2593084C (en) 2004-12-30 2014-03-18 Bioresponse, Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
BRPI0717753B1 (pt) 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
JP5524041B2 (ja) * 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
EP2213665A1 (en) 2007-08-17 2010-08-04 Hetero Drugs Limited Erlotinib hydrochloride
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 N-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
EP2411373B1 (en) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP0817775B1 (en) * 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
AU2850999A (en) 1999-11-16
AP9901523A0 (en) 1999-06-30
MEP42008A (en) 2011-02-10
NO20005453D0 (no) 2000-10-27
MXPA00010610A (es) 2002-07-02
AP1252A (en) 2004-02-25
CO5060467A1 (es) 2001-07-30
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
WO1999055683A1 (en) 1999-11-04
SA99200216B1 (ar) 2006-06-04
OA11769A (en) 2005-07-25
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
AU759691C (en) 2004-04-29
ATE295839T1 (de) 2005-06-15
TR200003166T2 (tr) 2001-02-21
JP4652569B2 (ja) 2011-03-16
HU227569B1 (en) 2011-08-29
DE69925366D1 (de) 2005-06-23
HK1037180A1 (en) 2002-02-01
KR100668412B1 (ko) 2007-01-12
EA200001112A1 (ru) 2001-04-23
UA60363C2 (uk) 2003-10-15
CZ298230B6 (cs) 2007-08-01
AR018201A1 (es) 2001-10-31
CA2330447C (en) 2009-06-30
ZA992972B (en) 2000-10-30
MY136033A (en) 2008-07-31
BR9910025A (pt) 2000-12-26
PE20000441A1 (es) 2000-05-23
CN1298396A (zh) 2001-06-06
PA8471001A1 (es) 2000-09-29
ID27198A (id) 2001-03-08
NZ508154A (en) 2003-07-25
ES2238825T3 (es) 2005-09-01
CZ20003974A3 (en) 2001-05-16
PL196940B1 (pl) 2008-02-29
NO317301B1 (no) 2004-10-04
NO20005453L (no) 2000-12-20
JP2002513009A (ja) 2002-05-08
HUP0101818A1 (hu) 2002-03-28
KR20010078710A (ko) 2001-08-21
MA26624A1 (fr) 2004-12-20
HN1999000057A (es) 1999-09-29
TWI248437B (en) 2006-02-01
EG24000A (en) 2008-03-19
CN101219999A (zh) 2008-07-16
EP1076652A1 (en) 2001-02-21
GT199900063A (es) 2000-10-20
PL343766A1 (en) 2001-09-10
AU759691B2 (en) 2003-04-17
EP1076652B1 (en) 2005-05-18
HUP0101818A3 (en) 2002-05-28
CA2330447A1 (en) 1999-11-04
RS50081B (sr) 2009-01-22
EA002836B1 (ru) 2002-10-31
TNSN99079A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
IL139172A0 (en) N- (3-ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4- quinazolinamine mesylate anhydrate and monohydrate
AU1047402A (en) Quinoline and quinazoline derivatives
AP2002002542A0 (en) Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride methods of production and pharmaceutical uses thereof
DE69940128D1 (de) Chinazolin- und Pyridopyrimidinderivate
SI1676845T1 (sl) Novi kinazolinski derivati
AU7860901A (en) Quinazoline derivatives
DE69910314D1 (de) Gruppenantenne und Funkgerät
IL134013A (en) Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors
GB2332993B (en) Fully integrated ballast ic
HUP0203430A3 (en) Quinazolinones and their use
ZA97913B (en) Substituted quinazolines derivatives
GB9607729D0 (en) Quinazoline derivatives
PL1646613T3 (pl) Chinolinowe i chinazolinowe pochodne mające powinowactwo do receptorów typu 5HT1
PL347721A1 (en) Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
DE69903961D1 (de) Muscarinagonisten und antagonisten
IL133036A0 (en) Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
ZA985326B (en) Aminospiropiperidine quinazoline derivatives
GB0030989D0 (en) Quinazoline derivatives
GB0015376D0 (en) Quinazoline derivatives
CA89002S (en) Base for roof ventilator
ZA200109864B (en) Quinazoline derivatives.
ZA200202930B (en) Methods and compositions utilizing quinazolinones.
GB9603049D0 (en) Quinazoline derivatives
GB0123775D0 (en) Roof ladders and arrangements therefor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees